Quarterly ResultMay 14, 2026, 04:14 PM
MetaVia DA-1726 Phase 1 Shows 9.1% Weight Loss; Q1 Net Loss $3.8M
AI Summary
MetaVia Inc. reported its first quarter 2026 financial results, with a net loss of $3.8 million. The company highlighted significant clinical progress for its lead obesity candidate, DA-1726, with Phase 1 data demonstrating 9.1% weight loss and improved glucose control. MetaVia also announced the dosing of the first patient in the Phase 1 Part 3 titration study for DA-1726, with data anticipated in the fourth quarter of 2026. The company's cash and cash equivalents increased to $13.7 million, supported by a $9.3 million public offering in January, providing runway into Q4 2026.
Key Highlights
- DA-1726 Phase 1 data showed 9.1% weight loss, improved glucose control, and direct liver benefit.
- First patient dosed in Phase 1 Part 3 16-week titration study for DA-1726; data expected Q4 2026.
- Net loss for Q1 2026 was $3.8 million, or $0.79 per basic and diluted share.
- Research and Development expenses decreased to $2.1 million in Q1 2026 from $2.3 million YoY.
- General and Administrative expenses increased to $1.9 million in Q1 2026 from $1.6 million YoY.
- Cash and cash equivalents were $13.7 million as of March 31, 2026, up from $10.2 million.
- Company expects cash position to fund operations into Q4 2026.
- Secured $9.3 million gross proceeds from a public offering in January 2026.